Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential

doi:10.12998/wjcc.v10.i1.23

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4596)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

303

WORD

109

HTML

2265

Figures (1-2)

429

Tables (1-1)

662

Sum=3768

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

254

Download

574

Sum=828

Jan 7, 2022 (publication date) through Jan 6, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jan 7, 2022; 10(1): 23-34
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.23

Full Size Figure Download Figure

Figure 2 The potential therapeutics mediated by interleukin-33/suppressor of tumorigenicity 2 in colorectal cancer.

Citation: Huang F, Chen WY, Ma J, He XL, Wang JW. Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential. World J Clin Cases 2022; 10(1): 23-34
URL: https://www.wjgnet.com/2307-8960/full/v10/i1/23.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i1.23